EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained‐Release Tablets in Depression With Anhedonia: A Single‐Arm, Multicenter Clinical Study

San-Wang Wang iD, Wei-Feng Mi iD, Xiao-Nan Hao iD, Xiao-Xing Liu iD, Xin Wen iD, Min Zhao iD, Hai-Feng Jiang iD, Wen-Zheng Wang iD, Tao Li iD, Zhong-Lin Tan iD, Song Chen iD, Wen Lv iD und 13 weitere

Depression and Anxiety · 2025-01 · 2025 (1)

DOI: 10.1155/da/6130764 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Depression and Anxiety, online erschienen am 06.05.2025. Verfasst von San-Wang Wang und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Anhedonia, Antidepressive Agents, Desvenlafaxine Succinate, Major Depressive Disorder. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toludesvenlafaxine hydrochloride sustained‐release tablets, as China’s first independently developed chemical Class 1 innovative drug with independent intellectual property rights for the treatment of depression and a new molecular entity, represent a novel triple reuptake inhibitor (TRI) with specific target selectivity for serotonin (5‐HT), norepinephrine (NE), and dopamine (DA). This single‐arm, multicenter clinical study aimed to evaluate the efficacy and safety of toludesvenlafaxine in alleviating anhedonia symptoms in patients with major depressive disorder (MDD). A total of 123 patients aged 18–65 years were enrolled between April 2023 and April 2024 and received an 8‐week treatment with toludesvenlafaxine sustained‐release tablets (80–160 mg/day). The primary efficacy endpoint was the change in the total score of the Dimensional Anhedonia Rating Scale (DARS) at weeks 2, 4, and 8. Significant improvements in DARS scores were observed, with mean changes from baseline of 8.4 (95% CI [6.4, 10.4], p < 0.0001), 14.1 (95% CI [12.0, 16.2], p < 0.0001), and 20.4 (95% CI [18.0, 22.9], p < 0.0001), respectively. Additionally, after 8 weeks of treatment, plasma levels of neurotrophic factors, including mature brain‐derived neurotrophic factor (mBDNF) ( t = 28.78, p < 0.0001), pro‐BDNF ( t = 27.71, p < 0.0001), and vascular endothelial growth factor (VEGF) ( t = 31.07, p < 0.0001), were significantly increased, and the plasma level of IGF‐1 was not significantly changed ( t = 0.35, p = 0.7269). No association was found between the percentage of changes in neurotrophic factors and the percentage of symptom improvements. Toludesvenlafaxine was generally well‐tolerated, with treatment‐emergent adverse events (AEs) (TEAEs) reported in 83.7% of participants and treatment‐related AEs (TRAEs) in 76.4%. These findings indicate that toludesvenlafaxine hydrochloride sustained‐release tablets are safe, well‐tolerated, and effective in alleviating anhedonia symptoms in patients with depression. Trial Registration: http://www.chictr.org.cn (No.: ChiCTR2300070331).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnhedoniaAntidepressive AgentsDesvenlafaxine SuccinateMajor Depressive DisorderOutcome Assessment, Health CareAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultDelayed-Action PreparationsTabletsTreatment Outcome

Stichwörter der Autor:innen

anhedoniadepressionmulticenter clinical studytoludesvenlafaxine

Substanzen

Antidepressive AgentsDelayed-Action PreparationsDesvenlafaxine SuccinateTablets

Autor:innen und Institutionen

  • Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China.
  • Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Ho…
  • Peking-Tsinghua Center for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China.
  • Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Affiliated Mental Health Centre and Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.

ORCID-Profile: San-Wang Wang, Wei-Feng Mi, Xiao-Nan Hao, Xiao-Xing Liu, Xin Wen, Min Zhao, Hai-Feng Jiang, Wen-Zheng Wang, Tao Li, Zhong-Lin Tan, Song Chen, Wen Lv, Yu-Ping Ning, Yan-Ling Zhou, Ying-Mei Chen, Xiang-Dong Tang, Bin Li, Yang Liu, Xian-Cang Ma, Ying-Ying Dong, Yun-Chun Chen, Hui-Ling Wang, Yong-Lan Huang, Lin Lu

Zitieren

APA

Wang, S. W., Mi, W. F., Hao, X. N., Liu, X. X., Wen, X., Zhao, M., Jiang, H. F., Wang, W. Z., Li, T., Tan, Z. L., Chen, S., Lv, W., Ning, Y. P., Zhou, Y. L., Chen, Y. M., Tang, X. D., Li, B., Liu, Y., Ma, X. C., …, & Lu, L. (2025). Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained‐Release Tablets in Depression With Anhedonia: A Single‐Arm, Multicenter Clinical Study. Depression and Anxiety, 2025(1). https://doi.org/10.1155/da/6130764

Vancouver

Wang SW, Mi WF, Hao XN, Liu XX, Wen X, Zhao M, et al. Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained‐Release Tablets in Depression With Anhedonia: A Single‐Arm, Multicenter Clinical Study. Depression and Anxiety. 2025;2025(1). doi:10.1155/da/6130764

BibTeX
@article{Wang2025,
  author = {Wang, San-Wang and Mi, Wei-Feng and Hao, Xiao-Nan and Liu, Xiao-Xing and Wen, Xin and Zhao, Min and Jiang, Hai-Feng and Wang, Wen-Zheng and Li, Tao and Tan, Zhong-Lin and Chen, Song and Lv, Wen and Ning, Yu-Ping and Zhou, Yan-Ling and Chen, Ying-Mei and Tang, Xiang-Dong and Li, Bin and Liu, Yang and Ma, Xian-Cang and Dong, Ying-Ying and Chen, Yun-Chun and Wang, Hui-Ling and Huang, Yong-Lan and Zhang, Hua and Lu, Lin},
  title = {Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained‐Release Tablets in Depression With Anhedonia: A Single‐Arm, Multicenter Clinical Study},
  journal = {Depression and Anxiety},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/da/6130764}
}
Kostenlos starten →